A Phase II, Randomized, Multi-center Study of Cabazitaxel Versus Abiraterone or Enzalutamide in Poor Prognosis-metastatic Castration-resistant Prostate Cancer
Phase of Trial: Phase II
Latest Information Update: 07 Mar 2017
At a glance
- Drugs Cabazitaxel (Primary) ; Abiraterone; Enzalutamide
- Indications Prostate cancer
- Focus Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 08 Dec 2016 Planned primary completion date changed from 1 Oct 2016 to 1 May 2020.
- 24 Feb 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.